{"id":44835,"date":"2022-06-08T13:01:56","date_gmt":"2022-06-08T11:01:56","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-announces-data-presentations-at-the-european-association-for-the-study-of-the-liver-easl-international-liver-congress-2022\/"},"modified":"2022-06-08T13:01:56","modified_gmt":"2022-06-08T11:01:56","slug":"enanta-pharmaceuticals-announces-data-presentations-at-the-european-association-for-the-study-of-the-liver-easl-international-liver-congress-2022","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-announces-data-presentations-at-the-european-association-for-the-study-of-the-liver-easl-international-liver-congress-2022\/","title":{"rendered":"Enanta Pharmaceuticals Announces Data Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress\u2122 2022"},"content":{"rendered":"
\n

WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that data from Enanta\u2019s internal development program portfolio for hepatitis B virus (HBV) and its out-licensing program portfolio for non-alcoholic steatohepatitis (NASH) have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) International Liver Congress 2022 being held June 22 \u2013 26, 2022 in London, United Kingdom.\n<\/p>\n

<\/a><\/p>\n

\nClinical data presented from the company\u2019s internal development portfolio will include poster presentations highlighting findings from both viremic and nuc-suppressed HBV patients from Phase 1b studies of EDP-514, Enanta\u2019s HBV core inhibitor.\n<\/p>\n

\nAs part of its out-licensing program portfolio, Enanta will present a late-breaker poster of preclinical data showing hepatoprotection provided by a novel inhibitor of the HSD17B13 enzyme. The company will also present clinical results from its Phase 1 study of EDP-297, a novel, highly potent Farnesoid X receptor agonist designed for the treatment of non-alcoholic steatohepatitis.\n<\/p>\n

\nInternal Development Programs<\/i><\/b>\n<\/p>\n

\nJune 25, 2022, 09:00 \u2013 18:00 BST
\n
<\/span>SAT390: \u201cEDP-514, a Novel Pangenotypic Class II Hepatitis B Virus Core Inhibitor: Final Results of a 28-Day Phase 1b Study in Nuc-Suppressed Chronic Hepatitis B Patients\u201d
\n
<\/b>Session: Viral Hepatitis B\/D: therapy
\n
Presenter: Dr. Jordan Feld\n<\/p>\n

\nSAT393: \u201cEDP-514, a Potent Pangenotypic Class II Hepatitis B Virus Core Inhibitor Demonstrates Significant HBV DNA and HBV RNA Reductions in a Phase 1b Study in Viremic, Chronic Hepatitis B Patients\u201d
\n
<\/b>Session: Viral Hepatitis B\/D: therapy
\n
Presenter: Dr. Man-Fung Yuen\n<\/p>\n

\nOut-Licensing Programs<\/i><\/b>\n<\/p>\n

\nJune 25, 2022, 09:00 \u2013 18:00 BST
\n
<\/span>SAT109: \u201cEDP-297: A Novel, Highly Potent, Farnesoid X Receptor Agonist. Results of a Phase 1 Study in Healthy Adults\u201d
\n
<\/b>Session: NAFLD: Therapy
\n
Presenter: Dr. Alaa Ahmad\n<\/p>\n

\nSAT177: \u201cPharmacologic Inhibition of HSD17B13 is Hepatoprotective in Mouse Models of Liver Injury\u201d
\n
<\/b>Session: Molecular and Cell Biology
\n
Presenter: Dr. Manuel Roqueta-Rivera\n<\/p>\n

\nThe full scientific program for The International Liver Congress 2022, as well as the abstracts, can be found at https:\/\/easl.eu\/event\/international-liver-congress-2022\/<\/a>. Further details will be available at the time of these presentations.\n<\/p>\n

\nAbout Enanta Pharmaceuticals, Inc.
\n
<\/b>Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta\u2019s research and development programs include clinical candidates currently in development for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research in human metapneumovirus (hMPV).\n<\/p>\n

\nEnanta\u2019s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic HCV infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET\u00ae (U.S.) and MAVIRET\u00ae (ex-U.S.) (glecaprevir\/pibrentasvir). Please visit www.enanta.com<\/a> for more information.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia and Investor Contact<\/b>
Jennifer Viera
\n
617-744-3848
\n
jviera@enanta.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that data from Enanta\u2019s internal development program portfolio for hepatitis B virus (HBV) and its out-licensing program portfolio for non-alcoholic steatohepatitis (NASH) have been accepted for poster presentations at the European … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-44835","6":"format-standard","7":"category-industry"},"yoast_head":"\nEnanta Pharmaceuticals Announces Data Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress\u2122 2022 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-announces-data-presentations-at-the-european-association-for-the-study-of-the-liver-easl-international-liver-congress-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Enanta Pharmaceuticals Announces Data Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress\u2122 2022 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that data from Enanta\u2019s internal development program portfolio for hepatitis B virus (HBV) and its out-licensing program portfolio for non-alcoholic steatohepatitis (NASH) have been accepted for poster presentations at the European ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-announces-data-presentations-at-the-european-association-for-the-study-of-the-liver-easl-international-liver-congress-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-08T11:01:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220608005136\/en\/1475183\/21\/Enanta_RGB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-announces-data-presentations-at-the-european-association-for-the-study-of-the-liver-easl-international-liver-congress-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-announces-data-presentations-at-the-european-association-for-the-study-of-the-liver-easl-international-liver-congress-2022\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Enanta Pharmaceuticals Announces Data Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress\u2122 2022\",\"datePublished\":\"2022-06-08T11:01:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-announces-data-presentations-at-the-european-association-for-the-study-of-the-liver-easl-international-liver-congress-2022\\\/\"},\"wordCount\":512,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-announces-data-presentations-at-the-european-association-for-the-study-of-the-liver-easl-international-liver-congress-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220608005136\\\/en\\\/1475183\\\/21\\\/Enanta_RGB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-announces-data-presentations-at-the-european-association-for-the-study-of-the-liver-easl-international-liver-congress-2022\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-announces-data-presentations-at-the-european-association-for-the-study-of-the-liver-easl-international-liver-congress-2022\\\/\",\"name\":\"Enanta Pharmaceuticals Announces Data Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress\u2122 2022 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-announces-data-presentations-at-the-european-association-for-the-study-of-the-liver-easl-international-liver-congress-2022\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-announces-data-presentations-at-the-european-association-for-the-study-of-the-liver-easl-international-liver-congress-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220608005136\\\/en\\\/1475183\\\/21\\\/Enanta_RGB.jpg\",\"datePublished\":\"2022-06-08T11:01:56+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-announces-data-presentations-at-the-european-association-for-the-study-of-the-liver-easl-international-liver-congress-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-announces-data-presentations-at-the-european-association-for-the-study-of-the-liver-easl-international-liver-congress-2022\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-announces-data-presentations-at-the-european-association-for-the-study-of-the-liver-easl-international-liver-congress-2022\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220608005136\\\/en\\\/1475183\\\/21\\\/Enanta_RGB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220608005136\\\/en\\\/1475183\\\/21\\\/Enanta_RGB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-announces-data-presentations-at-the-european-association-for-the-study-of-the-liver-easl-international-liver-congress-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Enanta Pharmaceuticals Announces Data Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress\u2122 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Enanta Pharmaceuticals Announces Data Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress\u2122 2022 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-announces-data-presentations-at-the-european-association-for-the-study-of-the-liver-easl-international-liver-congress-2022\/","og_locale":"en_US","og_type":"article","og_title":"Enanta Pharmaceuticals Announces Data Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress\u2122 2022 - Pharma Trend","og_description":"WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that data from Enanta\u2019s internal development program portfolio for hepatitis B virus (HBV) and its out-licensing program portfolio for non-alcoholic steatohepatitis (NASH) have been accepted for poster presentations at the European ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-announces-data-presentations-at-the-european-association-for-the-study-of-the-liver-easl-international-liver-congress-2022\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-08T11:01:56+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220608005136\/en\/1475183\/21\/Enanta_RGB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-announces-data-presentations-at-the-european-association-for-the-study-of-the-liver-easl-international-liver-congress-2022\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-announces-data-presentations-at-the-european-association-for-the-study-of-the-liver-easl-international-liver-congress-2022\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Enanta Pharmaceuticals Announces Data Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress\u2122 2022","datePublished":"2022-06-08T11:01:56+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-announces-data-presentations-at-the-european-association-for-the-study-of-the-liver-easl-international-liver-congress-2022\/"},"wordCount":512,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-announces-data-presentations-at-the-european-association-for-the-study-of-the-liver-easl-international-liver-congress-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220608005136\/en\/1475183\/21\/Enanta_RGB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-announces-data-presentations-at-the-european-association-for-the-study-of-the-liver-easl-international-liver-congress-2022\/","url":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-announces-data-presentations-at-the-european-association-for-the-study-of-the-liver-easl-international-liver-congress-2022\/","name":"Enanta Pharmaceuticals Announces Data Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress\u2122 2022 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-announces-data-presentations-at-the-european-association-for-the-study-of-the-liver-easl-international-liver-congress-2022\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-announces-data-presentations-at-the-european-association-for-the-study-of-the-liver-easl-international-liver-congress-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220608005136\/en\/1475183\/21\/Enanta_RGB.jpg","datePublished":"2022-06-08T11:01:56+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-announces-data-presentations-at-the-european-association-for-the-study-of-the-liver-easl-international-liver-congress-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-announces-data-presentations-at-the-european-association-for-the-study-of-the-liver-easl-international-liver-congress-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-announces-data-presentations-at-the-european-association-for-the-study-of-the-liver-easl-international-liver-congress-2022\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220608005136\/en\/1475183\/21\/Enanta_RGB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220608005136\/en\/1475183\/21\/Enanta_RGB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-announces-data-presentations-at-the-european-association-for-the-study-of-the-liver-easl-international-liver-congress-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Enanta Pharmaceuticals Announces Data Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress\u2122 2022"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44835","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44835"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44835\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44835"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44835"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44835"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}